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Loci identified through genome-wide association studies 
and lung cancer risk: is there anything more?
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Dear Editor,
Recently, lung cancer screening has acquired a position of central interest among the sci-
entific community. Many risk factors for non-small-cell lung cancer (NSCLC) susceptibility 
have already been identified, such as tobacco exposure, occupational exposure, random expo-
sure, silicosis and passive smoking.1,2 This knowledge has raised certain questions: Is there any 
clinical tool suitable for screening for NSCLC with good cost-effectiveness? Is there any thera-
peutic choice that could improve NSCLC case prognoses through an early approach? Is there 
any specific population that benefit from NSCLC screening and strategies for implementing 
an early approach? 
In 2009, a genome-wide association study (GWAS) was conducted on more than 5,000 
lung cancer cases.3 It was reported that some genetic polymorphisms located on chromo-
somes 5p15.33 and 15q25.1 were associated with a risk of adenocarcinoma in a Western 
population.3 In May 2012, Ito et al.4 assessed the genotyping in 716 Japanese lung cancer 
cases and 716 matched controls. This Japanese study showed that the variants rs12914385 
and rs931794 on 15q25 modified the effect of cumulative tobacco smoking on lung can-
cer risk, but that these two loci showed no statistically significant main effects on lung 
cancer risk. Furthermore, they reported that the associations shown by the TERT-CLPM1L 
locus on 5p15 with lung cancer risk among Japanese patients were of a similar magni-
tude to those among Western patients.4 Meanwhile, a Portuguese study5 reported that epi-
dermal growth factor (EGF)+61 genetic A/G polymorphisms were also associated with 
increased risk of NSCLC in a Portuguese population. EGF +61 A/G genetic polymorphisms 
are located on chromosome 4 and have also previously been reported to be risk factors for 
glioma and predictive biomarkers for cetuximab in colorectal cancer cases.5 
In this manner, the genome has now acquired a central role in NSCLC susceptibility.3-6 
Recent studies have shown that low-dose computed tomography could serve as an important 
screening tool in selected populations.5 Currently, many therapeutic options are possible for 
NSCLC treatment: surgery for the early stages, and also target therapies for advanced cases 
with good performance status.2,7 We believe that taking genome studies into consideration 
in identifying populations at risk could improve NSCLC screening strategies and therefore 
would help oncologists to implement prompt approaches.
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